Incyte, a U.S.-based global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines, announced the opening of the Incyte BioPlant in Y-PARC, Switzerland’s largest technology park located in Yverdon-les-Bains.
This new multi-product, high-efficiency, facility consists of a 13,300 square meter campus composed of three buildings housing production, technical operations and analytical labs. At full capacity, the Incyte BioPlant can house approximately 130 employees with expertise in manufacturing, quality control, process development, process engineering, plant engineering, maintenance, quality assurance and supply chain.
“We are proud to officially open our new BioPlant and begin production of important, potentially life-saving, medicines for patients with cancer,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We believe this new facility exemplifies our commitment to driving collaborative innovation, and we want to thank our partners, including the City of Yverdon, Canton du Vaud and Y-PARC, for their support and cooperation throughout this project.”
“The opening of the Incyte Bioplant site reinforces the numerous expertise and skills in the field of biomanufacturing that already exist in Canton of Vaud. It contributes to the creation of jobs with very high added value in the heart of the Health Valley and thus further establishes the Canton of Vaud as a major innovation hub in the field of life sciences. The Government of the State of Vaud thanks the management team of Incyte for the significant investment made on the Y-PARC technology park,” said Philippe Leuba, State Councilor, Head of Department of Economic Affairs, Innovation and Sport, Canton Vaud.
The BioPlant can manufacture biologically active pharmaceutical ingredients (API) for commercial and clinical use. It also includes laboratory space for process development and optimization, and will be focused on producing oncology products, specifically monoclonal antibodies (mAbs).
Pierre Dessemontet, Mayor of Yverdon-les-Bains, added, “The City of Yverdon-les-Bains is proud to welcome such a key player in the biopharmaceutic industry to Y-PARC. The opening of Incyte’s new facility is yet another example of our city and our region’s economic vitality and growth over the recent years. In addition to leading cutting-edge research and development in the field of oncology, Incyte’s new BioPlant will also allow for the creation of additional employment opportunities in Yverdon-les-Bains.”
“Y-PARC is proud and honored to count the Incyte BioPlant among 200 other innovative companies located on the park. Y-PARC’s DNA is to offer an appropriate environment to favor companies’ future development and a stimulating ecosystem with local high-tech competence. We are looking forward to collaborating and writing a new chapter in our collaboration with Incyte,” said Olivier Collet, Interim Director of Y-PARC.
Incyte is pursuing site qualifications for the Bioplant via Swissmedic/European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).